Neurocognitive Impairment in Non-Central Nervous System Cancer Survivors

被引:1
作者
Schoenberg, Poppy L. A. [1 ,2 ]
Mohr, Emily M. [2 ]
Kilpatrick, Phyllis E. [3 ]
Murphy, Barbara A. [3 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Phys Med & Rehabil, Nashville, TN 37203 USA
[2] Vanderbilt Univ, Med Ctr, Osher Ctr Integrat Hlth, 3401 West End,Suite 380, Nashville, TN 37203 USA
[3] Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Nashville, TN USA
关键词
cancer; neurocognitive impairment; electrophysiology; ERPs; executive function; EVENT-RELATED POTENTIALS; COGNITIVE THERAPY; NECK-CANCER; HEAD; PERFORMANCE; MODULATION; COMPONENT; INDEX; ERPS; N1;
D O I
10.1027/0269-8803/a000326
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Cancer and its treatments entail a profound inflammatory response of the central nervous system (CNS). This intense neurotoxic process can lead to significant neurocognitive impairment even in non-CNS cancers. Few studies have examined this domain, and data available is based on limited designs using neuropsychological assessments comprising self-report or traditional testing batteries that capture basic response data. Here, we leverage cognitive electrophysiology, specifically Event-Related Potentials (ERPs), to examine and delineate neurocognitive impairments in non-CNS cancer survivors. Eleven survivors, who were on average 4.6 years in remission from head and neck cancer and 10 matched healthy controls underwent standardized cognitive and emotional "Go-Nogo" paradigms concomitant to EEG recording. Significant differences in amplitude morphology in the very early ERP components (C1, N1, P1) and middle ERP component (N2), were apparent between non-CNS cancer survivors and controls. Later ERP components (P3, N4) did not show amplitude differences. Non-CNS cancer survivors yielded faster latencies in the early components for pain-related stimuli during the emotional paradigm, albeit tended to yield slower ERP latencies overall across both experiments. These findings suggest that early gating and inhibitory control are dysregulated in non-CNS cancer survivors, which can impact executive functioning and cognitive processing involved in everyday activities for many years post-treatment. The findings do not fully align with ERP morphologies associated with neurocognitive impairment in degenerative conditions (such as dementia and Alzheimer's disease), affecting later-stage ERP components. Our initial results suggest that (1) cognitive impairments in cancer survivors do not follow a degenerative trajectory, (2) rather are in line with "lesion" related damage (such as stroke, epilepsy), and as such, (3) have the potential for treatments involving neurocognitive plasticity.
引用
收藏
页码:11 / 27
页数:17
相关论文
共 50 条
[41]   Imaging of Cancer Therapy-Induced Central Nervous System Toxicity [J].
Dietrich, Joerg ;
Klein, Joshua P. .
NEUROLOGIC CLINICS, 2014, 32 (01) :147-+
[42]   Neurologic complications of cancer Part 1: Central nervous system metastasis [J].
Tasdemiroglu, E ;
Kaya, AH ;
Bek, S ;
Emir, CB ;
Sengoz, A ;
Kilickesmez, O ;
Mansuroglu, I .
NEUROSURGERY QUARTERLY, 2004, 14 (02) :71-83
[43]   The effect of pediatric central nervous system tumors on identity in young adult survivors: a project REACH study [J].
Cacciotti, Chantel ;
Chevalier, Lydia Larocque ;
Medeiros-Nancarrow, Cheryl ;
Recklitis, Christopher ;
Cooney, Tabitha M. .
JOURNAL OF CANCER SURVIVORSHIP, 2023, 17 (05) :1347-1358
[44]   The effect of pediatric central nervous system tumors on identity in young adult survivors: a project REACH study [J].
Chantel Cacciotti ;
Lydia Larocque Chevalier ;
Cheryl Medeiros-Nancarrow ;
Christopher Recklitis ;
Tabitha M. Cooney .
Journal of Cancer Survivorship, 2023, 17 :1347-1358
[45]   Mortality patterns in long-term survivors of childhood or adolescent central nervous system tumour in Sweden [J].
Huang, Wuqing ;
Sundquist, Jan ;
Sundquist, Kristina ;
Ji, Jianguang .
JOURNAL OF NEURO-ONCOLOGY, 2019, 145 (03) :541-549
[46]   In-vivo magnetic resonance spectroscopy of lactate as a non-invasive biomarker of dichloroacetate activity in cancer and non-cancer central nervous system disorders [J].
Kamson, David O. ;
Chinnasamy, Viveka ;
Grossman, Stuart A. ;
Bettegowda, Chetan ;
Barker, Peter B. ;
Stacpoole, Peter W. ;
Oeltzschner, Georg .
FRONTIERS IN ONCOLOGY, 2023, 13
[47]   The usefulness of non-human primates in central nervous system safety pharmacology [J].
Porsolt, Roger D. .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 68 (01) :23-29
[48]   Excessive daytime sleepiness and sleep-disordered breathing disturbances in survivors of childhood central nervous system tumors [J].
Mandrell, Belinda N. ;
Wise, Merrill ;
Schoumacher, Robert A. ;
Pritchard, Michele ;
West, Nancy ;
Ness, Kirsten K. ;
Crabtree, Valerie McLaughlin ;
Merchant, Thomas E. ;
Morris, Brannon .
PEDIATRIC BLOOD & CANCER, 2012, 58 (05) :746-751
[49]   Nanotechnologies for the study of the central nervous system [J].
Ajetunmobi, A. ;
Prina-Mello, A. ;
Volkov, Y. ;
Corvin, A. ;
Tropea, D. .
PROGRESS IN NEUROBIOLOGY, 2014, 123 :18-36
[50]   Aging, the Central Nervous System, and Mobility [J].
Rosso, Andrea L. ;
Studenski, Stephanie A. ;
Chen, Wen G. ;
Aizenstein, Howard J. ;
Alexander, Neil B. ;
Bennett, David A. ;
Black, Sandra E. ;
Camicioli, Richard ;
Carlson, Michelle C. ;
Ferrucci, Luigi ;
Guralnik, Jack M. ;
Hausdorff, Jeffrey M. ;
Kaye, Jeff ;
Launer, Lenore J. ;
Lipsitz, Lewis A. ;
Verghese, Joe ;
Rosano, Caterina .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2013, 68 (11) :1379-1386